At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Regorafenib and PD-1 Antibody in Combination With Radiotherapy With or Without SBRT in Patients With pMMR/MSS and Previously Treated Metastatic Colorectal Cancer
In Brief
A Phase 2 clinical trial evaluating Regorafenib and PD-1 antibody in Combination with Radiotherapy and Radiation therapy for Colorectal Cancer Metastatic and MSS. Targeting 28 participants across 1 site.
Detailed Summary
REGONIVO is a Phase Ib study to explore the efficacy and safety of regorafenib in combination with nivolumab in the treatment of gastric cancer and colorectal cancer with MSS. The study enrolled 50 patients with advanced disease, including 25 cases of gastric cancer, 25 cases of colorectal cancer, except for one case of colorectal cancer with MSI-H, and others were MSS type. The results of the study showed that patients with colorectal cancer had an objective response rate (ORR) of 36% and a progression-free survival (PFS) of 6.3 months. Based on the preliminary results of the REGONIVO study, the aim of this phase 2 study is to explore the safety and efficacy of regorafenib and PD-1 antibody with or without radiotherapy in previously treated metastatic colorectal cancer patients with pMMR/MSS.
Study Details
Timeline
Interventions
Regorafenib will be given 3 weeks on/1 week off (80 mg od po.) and PD-1 antibody
Radiation therapy is believed to increase the likelihood of response of immunotherapy